ReviewFrontiers in immunology2025
Common pathological mechanisms and therapeutic strategies in primary Sjogren's syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Bidirectional causal associations between Sjögren syndrome and gastrointestinal disorders: A two-sample Mendelian randomization study.Medicine · 2026Article
- Morphological and Immunohistochemical Characteristics of Liver Inflammation in Patients with a History of COVID-19.Viruses · 2026Article
- Identifying the clinical signature of anti-centromere antibody-positive Sjögren's syndrome: a machine learning-based analysis of a multicenter cohort.Frontiers in immunology · 2026Article
- Surgical removal of Waldeyer's ring and long-term risk of Sjögren's syndrome: a population-based cohort study investigating the mucosal immune link.Frontiers in immunology · 2026Article
- B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune diseases are characterized by their involvement of multiple organ systems and the presence of overlapping clinical manifestations among distinct disease entities. Both primary Sjogren's syndrome (pSS) and primary biliary cholangitis (PBC) are chronic inflammatory disorders driven by immune-mediated injury to glandular or ductal epithelial cells. Due to shared genetic susceptibility, epidemiological patterns, and pathophysiological mechanisms, these two diseases frequently coexist in clinical practices and demonstrate a common tissue immune microenvironment. Recent advances have greatly enhanced the understanding of pSS and PBC pathogenesis, particularly regarding autoantibody profiles and pro-inflammatory cytokine expression in serum, as well as the functional activity of immune cells within affected tissues. These insights provide new perspectives and potential avenues for the development of targeted therapeutic strategies. This review examines the associations between pSS and PBC, explores the shared immunological pathways involved in disease onset and progression, and summarizes common therapeutic targets within the context of clinical treatment. The goal is to provide a comprehensive perspective that may guide future research and inform improved diagnostic and therapeutic strategies for both conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.